Clinical Trial Update: KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) [Phase 1, Phase 2]

View source ↗

Summary

This is a Clinical Trial Update for KEYMAKER-U04, a Phase 1/2 study evaluating new treatments given with enfortumab vedotin and pembrolizumab in bladder/urothel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING